Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $8.16, but acceptable to hold if already in. Reason: Market cap $0.86B below $1B minimum.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as... Read more
Hold if already holding. Not a fresh buy at $8.16, but acceptable to hold if already in. Reason: Market cap $0.86B below $1B minimum. Chart setup: Death cross but MACD improving, RSI 46. Market cap $0.86B below $1B minimum. Not in investable universe. Score 5.0/10, moderate confidence.
Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Oric Pharmaceuticals, Inc.
Latest news
- NEWS Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session — benzinga Jun 15, 2026
- NEWS HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target — benzinga Jun 8, 2026
- NEWS Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16 — benzinga May 5, 2026
- NEWS ORIC Pharmaceuticals Q1 EPS $(0.34) Misses $(0.32) Estimate — benzinga May 4, 2026
- NEWS ORIC Pharmaceuticals Presents Multiple Poster Presentation At 2026 American Association For Cancer Research Annual Meeti — benzinga Apr 17, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $8.16, but acceptable to hold if already in. Reason: Market cap $0.86B below $1B minimum. Chart setup: Death cross but MACD improving, RSI 46. Market cap $0.86B below $1B minimum. Not in investable universe. Target $17.65 (+116.3%), stop $7.59 (−7.5%), A.R:R 7.8:1. Score 5.0/10, moderate confidence.
Take-profit target: $17.65 (+116.3% upside). Target $17.65 (+116.3%), stop $7.59 (−7.5%), A.R:R 7.8:1. Stop-loss: $7.59.
Market cap $0.86B below $1B minimum.
Oric Pharmaceuticals, Inc. trades at a P/E of N/A (forward -5.3). TrendMatrix value score: 9.0/10. Verdict: Hold.
22 analysts cover ORIC with a consensus score of 4.3/5. Average price target: $20.
What does Oric Pharmaceuticals, Inc. do?ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of...
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.